Literature DB >> 9845123

Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells.

J A Bonner1, B T Vroman, T J Christianson, L M Karnitz.   

Abstract

PURPOSE: Ionizing radiation (IR) triggers several intracellular signaling cascades that have commonly been regarded as mitogenic, including the Raf-MEK-Erk kinase cascade. In addition to promoting proliferation, activated MEK and Erk may also prevent cell death induced by cytotoxic stimuli. Because Raf, MEK, and Erk are activated by IR in some tumor cell lines, this suggests that IR-induced activation of the kinase cascade may enhance the survival of irradiated cells. METHODS AND MATERIALS: IR-induced activation of MEK and Erk was assessed in irradiated UM-SCC-6 cells, a human squamous carcinoma cell line. Activation of MEK and Erk was blocked with the pharmacological inhibitor of MEK activation, PD098059. Clonogenic survival was assessed in irradiated UM-SCC-6 cells that were pretreated with nothing or with the MEK inhibitor.
RESULTS: In UM-SCC-6 cells, IR doses as low as 2 Gy rapidly activated MEK and Erk. Pretreatment of the cells with the pharmacological inhibitor of MEK activation, PD098059, effectively blocked IR-induced activation of MEK and Erk. However, inhibition of the kinase cascade did not affect the clonogenic survival of irradiated cells in either early or delayed-plating experiments.
CONCLUSION: Taken together, these results suggest that although MEK and Erk are rapidly activated by IR treatment, these protein kinases do not affect the clonogenic survival of irradiated UM-SCC6 cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9845123     DOI: 10.1016/s0360-3016(98)00325-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells.

Authors:  J S Park; S Carter; D B Reardon; R Schmidt-Ullrich; P Dent; P B Fisher
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

Review 2.  Mitogen-activated protein kinases and their role in radiation response.

Authors:  Anupama Munshi; Rajagopal Ramesh
Journal:  Genes Cancer       Date:  2013-09

3.  In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.

Authors:  Eun Joo Chung; Aaron P Brown; Hiroaki Asano; Mariana Mandler; William E Burgan; Donna Carter; Kevin Camphausen; Deborah Citrin
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

4.  MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.

Authors:  Adriana Estrada-Bernal; Moumita Chatterjee; S Jaharul Haque; Linlin Yang; Meredith A Morgan; Shweta Kotian; David Morrell; Arnab Chakravarti; Terence M Williams
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.

Authors:  N Magné; J L Fischel; A Dubreuil; P Formento; S Marcié; J-L Lagrange; G Milano
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

Review 6.  Dual effects of active ERK in cancer: A potential target for enhancing radiosensitivity.

Authors:  Yinliang Lu; Baocai Liu; Ying Liu; Xinyue Yu; Guanghui Cheng
Journal:  Oncol Lett       Date:  2020-05-28       Impact factor: 2.967

7.  Kinase-independent role for CRAF-driving tumour radioresistance via CHK2.

Authors:  Sunil J Advani; Maria Fernanda Camargo; Laetitia Seguin; Ainhoa Mielgo; Sudarshan Anand; Angel M Hicks; Joseph Aguilera; Aleksandra Franovic; Sara M Weis; David A Cheresh
Journal:  Nat Commun       Date:  2015-09-03       Impact factor: 14.919

8.  Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.

Authors:  Hanneke Stegeman; Johannes H A M Kaanders; Marieke M G Verheijen; Wenny J M Peeters; Deric L Wheeler; Mari Iida; Reidar Grénman; Albert J van der Kogel; Paul N Span; Johan Bussink
Journal:  Mol Cancer       Date:  2013-11-05       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.